355 related articles for article (PubMed ID: 22982441)
1. Oncostatin M is a growth factor for Ewing sarcoma.
David E; Tirode F; Baud'huin M; Guihard P; Laud K; Delattre O; Heymann MF; Heymann D; Redini F; Blanchard F
Am J Pathol; 2012 Nov; 181(5):1782-95. PubMed ID: 22982441
[TBL] [Abstract][Full Text] [Related]
2. GP130/OSMR is the only LIF/IL-6 family receptor complex to promote osteoblast differentiation of calvaria progenitors.
Malaval L; Liu F; Vernallis AB; Aubin JE
J Cell Physiol; 2005 Aug; 204(2):585-93. PubMed ID: 15751050
[TBL] [Abstract][Full Text] [Related]
3. The AB loop and D-helix in binding site III of human Oncostatin M (OSM) are required for OSM receptor activation.
Adrian-Segarra JM; Schindler N; Gajawada P; Lörchner H; Braun T; Pöling J
J Biol Chem; 2018 May; 293(18):7017-7029. PubMed ID: 29511087
[TBL] [Abstract][Full Text] [Related]
4. Concomitant Activation of OSM and LIF Receptor by a Dual-Specific hlOSM Variant Confers Cardioprotection after Myocardial Infarction in Mice.
Lörchner H; Adrian-Segarra JM; Waechter C; Wagner R; Góes ME; Brachmann N; Sreenivasan K; Wietelmann A; Günther S; Doll N; Braun T; Pöling J
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008777
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells require PKCdelta and STAT3.
Chipoy C; Berreur M; Couillaud S; Pradal G; Vallette F; Colombeix C; Rédini F; Heymann D; Blanchard F
J Bone Miner Res; 2004 Nov; 19(11):1850-61. PubMed ID: 15476586
[TBL] [Abstract][Full Text] [Related]
6. Oncostatin M-specific receptor mediates inhibition of breast cancer cell growth and down-regulation of the c-myc proto-oncogene.
Liu J; Spence MJ; Wallace PM; Forcier K; Hellström I; Vestal RE
Cell Growth Differ; 1997 Jun; 8(6):667-76. PubMed ID: 9186000
[TBL] [Abstract][Full Text] [Related]
7. Oncostatin M (OSM) cytostasis of breast tumor cells: characterization of an OSM receptor beta-specific kernel.
Underhill-Day N; Heath JK
Cancer Res; 2006 Nov; 66(22):10891-901. PubMed ID: 17108126
[TBL] [Abstract][Full Text] [Related]
8. Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling.
Guihard P; Danger Y; Brounais B; David E; Brion R; Delecrin J; Richards CD; Chevalier S; Rédini F; Heymann D; Gascan H; Blanchard F
Stem Cells; 2012 Apr; 30(4):762-72. PubMed ID: 22267310
[TBL] [Abstract][Full Text] [Related]
9. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
10. Expression of short-form oncostatin M receptor as a decoy receptor in lung adenocarcinomas.
Chen D; Chu CY; Chen CY; Yang HC; Chiang YY; Lin TY; Chiang IP; Chuang DY; Yu CC; Chow KC
J Pathol; 2008 Jul; 215(3):290-9. PubMed ID: 18491353
[TBL] [Abstract][Full Text] [Related]
11. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
[TBL] [Abstract][Full Text] [Related]
12. EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.
Cidre-Aranaz F; Grünewald TG; Surdez D; García-García L; Carlos Lázaro J; Kirchner T; González-González L; Sastre A; García-Miguel P; López-Pérez SE; Monzón S; Delattre O; Alonso J
Oncogene; 2017 Feb; 36(6):766-776. PubMed ID: 27375017
[TBL] [Abstract][Full Text] [Related]
13. Phosphoproteomic profiling reveals IL6-mediated paracrine signaling within the Ewing sarcoma family of tumors.
Anderson JL; Titz B; Akiyama R; Komisopoulou E; Park A; Tap WD; Graeber TG; Denny CT
Mol Cancer Res; 2014 Dec; 12(12):1740-54. PubMed ID: 25092916
[TBL] [Abstract][Full Text] [Related]
14. Murine Oncostatin M Acts via Leukemia Inhibitory Factor Receptor to Phosphorylate Signal Transducer and Activator of Transcription 3 (STAT3) but Not STAT1, an Effect That Protects Bone Mass.
Walker EC; Johnson RW; Hu Y; Brennan HJ; Poulton IJ; Zhang JG; Jenkins BJ; Smyth GK; Nicola NA; Sims NA
J Biol Chem; 2016 Oct; 291(41):21703-21716. PubMed ID: 27539849
[TBL] [Abstract][Full Text] [Related]
15. Oncostatin M acting via OSMR, augments the actions of IL-1 and TNF in synovial fibroblasts.
Le Goff B; Singbrant S; Tonkin BA; Martin TJ; Romas E; Sims NA; Walsh NC
Cytokine; 2014 Aug; 68(2):101-9. PubMed ID: 24767864
[TBL] [Abstract][Full Text] [Related]
16. Oncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant mammary epithelial cells.
Liu J; Hadjokas N; Mosley B; Estrov Z; Spence MJ; Vestal RE
Cytokine; 1998 Apr; 10(4):295-302. PubMed ID: 9617575
[TBL] [Abstract][Full Text] [Related]
17. Coexpression of oncostatin M and its receptors and evidence for STAT3 activation in human ovarian carcinomas.
Savarese TM; Campbell CL; McQuain C; Mitchell K; Guardiani R; Quesenberry PJ; Nelson BE
Cytokine; 2002 Mar; 17(6):324-34. PubMed ID: 12061840
[TBL] [Abstract][Full Text] [Related]
18. Analysis of IL-6/gp130 family receptor expression reveals that in contrast to astroglia, microglia lack the oncostatin M receptor and functional responses to oncostatin M.
Hsu MP; Frausto R; Rose-John S; Campbell IL
Glia; 2015 Jan; 63(1):132-41. PubMed ID: 25103368
[TBL] [Abstract][Full Text] [Related]
19. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
Kovar H
Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
[TBL] [Abstract][Full Text] [Related]
20. Oncostatin M is a differentiation factor for myeloid leukemia cells.
Bruce AG; Hoggatt IH; Rose TM
J Immunol; 1992 Aug; 149(4):1271-5. PubMed ID: 1380037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
